|
5.5.1 ASCO (GÉNÉRAL)
|
|
|
ASCO 2019: Abstracts With High Impact Potential [OBR]
|
|
|
|
|
|
Don Sharpe, President and Founder of OBR, moderated the session, and the primary areas of focus included cervical, prostate, pancreatic, breast, lung, and advanced gastric/gastroesophageal junction cancers as well as multiple myeloma and hepatocellular carcinoma (HCC).
|
|
|
|
|
|
|
|
Drugs make headway against lung, breast, prostate cancers [AP]
|
|
|
|
|
|
The results were featured Saturday and Sunday at the American Society of Clinical Oncology conference in Chicago and some were published by the New England Journal of Medicine. Companies that make the drugs sponsored the studies, and some study leaders have financial ties.
|
|
|
|
|
|
|
5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
|
|
|
|
5.5.10 ASCO (HÉMATO)
|
|
|
|
|
|
|
|
|
5.5.15 ASCO (BIOPSIES LIQUIDES)
|
|
|
|
5.5.17 ASCO (PANCRÉAS)
|
|
|
|
|
|
|
|
5.5.18 ASCO (OBSERVATION)
|
|
|
The Affordable Care Act erased a racial disparity in cancer care, a new study says [STAT]
|
|
|
|
|
|
The American Society of Clinical Oncology chose the study for prime placement this weekend at the plenary session of its annual meeting, the world’s largest gathering of cancer doctors, squeezing it in between studies of state-of-the-art cancer drugs in a statement about the importance of health insurance in determining how well cancer patients are treated.
|
|
|
|
|
|
|
|
|
|
5.5.2 ASCO (SEIN)
|
|
|
|
|
|
|
|
|
|
|
|
|
5.5.3 ASCO (PROSTATE)
|
|
|
|
|
|
|
5.5.4 ASCO (IMMUNOTHÉRAPIES)
|
|
|
|
|
|
5.5.4.4 ASCO (IMMUNOTHÉRAPIES-POUMON)
|
|
|
|
|
|
|
|
|
|
|
5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)
|
|
|
|
|
|
|
5.5.4.7 ASCO (IMMUNOTHÉRAPIES- GASTRO-INTESTINAL)
|
|
|
|
|
|
|
5.5.8 ASCO (POUMON)
|
|
|
|
|
|
|
5.5.9 ASCO (AUTRES ORGANES)
|
|
|